암 백신 시장 : 제품 유형, 제제, 투여 경로, 치료 전략, 병기, 적응증, 최종 사용자별 - 세계 예측(2026-2032년)

The Cancer Vaccines Market is projected to grow by USD 21.28 billion at a CAGR of 10.66% by 2032.

Cancer Vaccines Executive Summary

Cancer vaccines are moving from a niche immuno-oncology concept to a strategic pillar of cancer prevention and treatment. The category includes proven preventive vaccines, such as human papillomavirus and hepatitis B vaccines, as well as therapeutic platforms designed to activate tumor-specific immune responses using neoantigens, peptides, dendritic cells, viral vectors, or mRNA.

The need is substantial: the International Agency for Research on Cancer estimated 20.0 million new cancer cases and 9.7 million cancer deaths worldwide in 2022, with more than 35 million new cases projected by 2050. This burden is accelerating investment in cancer vaccine development, combination immunotherapy, biomarker-led clinical trials, and scalable manufacturing models.

Transformative Shifts in the Cancer Vaccine Landscape

The cancer vaccines landscape is being reshaped by precision oncology, rapid sequencing, and the clinical validation of immunotherapy combinations. Development priorities are shifting from standardized tumor-associated antigen approaches toward personalized neoantigen vaccines tailored to each patient's tumor mutations and HLA profile.

At the same time, mRNA vaccine infrastructure built during the COVID-19 era has improved confidence in rapid design, production, and clinical deployment. Market participants are also prioritizing checkpoint inhibitor combinations, earlier-line treatment settings, and measurable residual disease strategies to improve response durability and demonstrate health-economic value.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is creating a cumulative advantage across the cancer vaccine value chain. AI models are increasingly used to predict neoantigen immunogenicity, evaluate HLA binding, analyze multi-omics datasets, identify patient subgroups, and optimize trial enrollment. These capabilities can shorten discovery timelines and improve the probability that selected antigens generate clinically meaningful immune responses.

AI is also strengthening manufacturing analytics, quality control, pharmacovigilance, and real-world evidence generation. However, industry leaders must pair AI-enabled speed with validated datasets, transparent model governance, regulatory documentation, and clinically interpretable outputs to support FDA, EMA, and other agency expectations.

Key Regional Insights for Cancer Vaccines

North America remains a leading region for cancer vaccine innovation due to deep oncology research networks, NCI-supported programs, FDA experience with immunotherapy regulation, and strong venture funding. The United States and Canada also benefit from high use of genomic testing, established clinical trial infrastructure, and broad adoption of immune checkpoint inhibitors, creating a favorable environment for therapeutic cancer vaccine combinations. Europe benefits from established cancer centers, EMA oversight, Horizon Europe research funding, and growing interest in advanced therapy manufacturing, although pricing, reimbursement, and health technology assessment requirements influence adoption across the European Union, the United Kingdom, and other European markets.

Asia-Pacific is expanding through China's clinical trial scale, Japan's regenerative medicine frameworks, South Korea's biologics capabilities, Australia's oncology trial ecosystem, and India's vaccine manufacturing base. The region also has major relevance for preventive cancer vaccines because WHO and national immunization programs continue to emphasize HPV vaccination for cervical cancer prevention and hepatitis B vaccination for liver cancer prevention. Latin America, the Middle East, and Africa present rising long-term demand driven by cervical, liver, and other infection-associated cancers. In Latin America, public immunization programs and oncology trial participation support access pathways, while the Middle East is investing in precision medicine, national genomics, and specialist cancer centers. Africa has a high need for preventive vaccination and early cancer detection, but access, cold-chain capacity, reimbursement, oncology workforce availability, and genomic infrastructure remain decisive constraints.

Key Group Insights Across Major Economic Blocs

Within ASEAN, cancer vaccine opportunities are linked to HPV vaccination expansion, regional trial participation, rising cancer screening initiatives, and growing biologics manufacturing ambition in countries such as Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines. The GCC is investing in precision medicine, national genomics, digital health records, and specialized cancer centers, positioning the group as a selective adopter of advanced immuno-oncology technologies and companion diagnostic-enabled cancer vaccine programs.

The European Union supports translational research, cross-border clinical development, regulatory standardization, and centralized evaluation of novel immunotherapies, while BRICS countries offer large patient populations, cost-efficient clinical development, and expanding biomanufacturing capacity across China, India, Brazil, Russia, and South Africa. G7 markets continue to shape reimbursement evidence, intellectual property standards, clinical trial quality, and regulatory expectations for personalized cancer vaccines. NATO member markets are also relevant through resilient supply chain planning, biosecurity priorities, cold-chain reliability, cross-border medical innovation networks, and coordinated preparedness for advanced biologics manufacturing.

Key Country Insights for Priority Cancer Vaccine Markets

The United States leads in cancer vaccine clinical trials, venture funding, FDA precedent, and academic-industry partnerships, while Canada contributes strong oncology research, population health datasets, and real-world evidence capabilities. Mexico and Brazil offer important Latin American trial access and public-health relevance for infection-related cancers, particularly cervical and liver cancer prevention. The United Kingdom, Germany, France, Italy, and Spain combine advanced cancer centers, genomic medicine programs, and mature regulatory pathways with evolving reimbursement scrutiny, while Russia remains scientifically active but affected by geopolitical, funding, and access constraints.

China is rapidly scaling domestic immuno-oncology pipelines, clinical trial enrollment, sequencing capacity, and biologics manufacturing. India combines high disease burden with large-scale vaccine manufacturing strength, expanding digital health infrastructure, and increasing oncology trial participation. Japan supports advanced therapies through mature regulation, strong translational science, and established oncology care pathways. Australia is a favored early-phase oncology trial hub due to efficient trial start-up processes, high-quality clinical sites, and diverse patient recruitment opportunities. South Korea is gaining visibility through biologics manufacturing, digital health infrastructure, national cancer screening experience, and precision oncology investment.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize platforms that demonstrate clear biological rationale, reproducible immune activation, and compatibility with combination regimens. Programs should be designed around validated biomarkers, robust companion diagnostics, and patient-selection strategies that can support regulatory review, clinical utility assessment, and payer acceptance.

Commercial readiness requires investment in sequencing logistics, individualized manufacturing capacity, cold-chain control, decentralized clinical workflows, and quality systems aligned with advanced biologics requirements. Organizations should also pursue partnerships with cancer centers, genomic testing providers, CDMOs, clinical research networks, and public-health organizations to improve trial speed, manufacturing reliability, equitable access, and evidence generation across diverse populations.

Research Methodology

This executive summary is based on triangulated secondary research and industry analysis using publicly available information from authoritative sources, including the WHO, IARC, FDA, EMA, ClinicalTrials.gov, peer-reviewed oncology journals, public regulatory documents, and major cancer research organizations.

The methodology emphasizes verified epidemiology, regulatory precedent, clinical development activity, technology trends, preventive vaccination evidence, and regional healthcare infrastructure. Insights were assessed for relevance to cancer vaccine commercialization, therapeutic development, preventive vaccination, manufacturing scalability, reimbursement readiness, regulatory feasibility, and competitive positioning across mature and emerging markets.

Conclusion

Cancer vaccines are entering a more commercially relevant phase as oncology shifts toward earlier intervention, personalized immunotherapy, and durable immune control. Preventive vaccination already provides proven cancer-reduction value, while therapeutic vaccine pipelines are becoming more sophisticated through mRNA platforms, neoantigen science, viral vectors, dendritic cell approaches, and AI-enabled antigen selection.

The strongest opportunities will favor organizations that combine clinical rigor with manufacturing agility, regulatory discipline, data infrastructure, and access planning. As cancer incidence rises globally, cancer vaccines are positioned to become an increasingly important component of precision oncology and population-level cancer prevention.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Cancer Vaccines Market, by Product Type

• 7.1. Preventive Cancer Vaccines
• 7.2. Therapeutic Cancer Vaccines

8. Cancer Vaccines Market, by Formulations

• 8.1. Cell-Based Vaccines
  • 8.1.1. Dendritic Cell Vaccines
  • 8.1.2. Tumor Cell Vaccines
• 8.2. Nucleic Acid-Based Vaccines
  • 8.2.1. DNA Vaccines
  • 8.2.2. RNA Vaccines
• 8.3. Peptide/Protein-Based Vaccines
• 8.4. Synthetic Vaccines
• 8.5. Viral Vector-Based Vaccines

9. Cancer Vaccines Market, by Route Of Administration

• 9.1. Intradermal
• 9.2. Subcutaneous
• 9.3. Intramuscular
• 9.4. Intravenous

10. Cancer Vaccines Market, by Treatment Strategy

• 10.1. Monotherapy
• 10.2. Combination Therapy

11. Cancer Vaccines Market, by Disease Stage

• 11.1. Early Stage
• 11.2. Locally Advanced
• 11.3. Metastatic
• 11.4. Recurrent Or Relapsed

12. Cancer Vaccines Market, by Indication

• 12.1. Solid Tumors
  • 12.1.1. Prostate Cancer
  • 12.1.2. Cervical Cancer
  • 12.1.3. Lung Cancer
  • 12.1.4. Melanoma
  • 12.1.5. Breast Cancer
  • 12.1.6. Colorectal Cancer
  • 12.1.7. Ovarian Cancer
  • 12.1.8. Bladder Cancer
  • 12.1.9. Head & Neck Cancer
• 12.2. Hematologic Malignancies
  • 12.2.1. Leukemia
  • 12.2.2. Lymphoma
  • 12.2.3. Multiple Myeloma

13. Cancer Vaccines Market, by End-User

• 13.1. Cancer Research Institutes
• 13.2. Hospitals & Clinics
• 13.3. Specialty Cancer Treatment Centers

14. Cancer Vaccines Market, by Region

• 14.1. Asia-Pacific
• 14.2. North America
• 14.3. Latin America
• 14.4. Europe
• 14.5. Middle East
• 14.6. Africa

15. Cancer Vaccines Market, by Group

• 15.1. ASEAN
• 15.2. GCC
• 15.3. European Union
• 15.4. BRICS
• 15.5. G7
• 15.6. NATO

16. Cancer Vaccines Market, by Country

• 16.1. United States
• 16.2. Canada
• 16.3. Mexico
• 16.4. Brazil
• 16.5. United Kingdom
• 16.6. Germany
• 16.7. France
• 16.8. Russia
• 16.9. Italy
• 16.10. Spain
• 16.11. China
• 16.12. India
• 16.13. Japan
• 16.14. Australia
• 16.15. South Korea

17. Competitive Landscape

• 17.1. Market Concentration Analysis, 2025
  • 17.1.1. Concentration Ratio (CR)
  • 17.1.2. Herfindahl Hirschman Index (HHI)
• 17.2. Recent Developments & Impact Analysis, 2025
• 17.3. Product Portfolio Analysis, 2025
• 17.4. Benchmarking Analysis, 2025

18. Company Profiles

• 18.1. Merck & Co., Inc.
• 18.2. GSK PLC
• 18.3. Dynavax Technologies Corporation
• 18.4. Serum Institute of India Pvt. Ltd.
• 18.5. Dendreon Pharmaceuticals LLC
• 18.6. JW CreaGene
• 18.7. Amgen Inc.
• 18.8. AstraZeneca PLC
• 18.9. BioNTech SE
• 18.10. Bristol Myers Squibb Company
• 18.11. Celldex Therapeutics, Inc.
• 18.12. CureVac SE
• 18.13. Eli Lilly and Company
• 18.14. F. Hoffmann-La Roche AG
• 18.15. Ferring B.V.
• 18.16. Helsinn Healthcare SA
• 18.17. Inovio Pharmaceuticals, Inc.
• 18.18. Johnson & Johnson Services, Inc
• 18.19. Moderna, Inc.
• 18.20. OS Therapies
• 18.21. Pfizer Inc.
• 18.22. Sanofi SA
• 18.23. Sun Pharmaceutical Industries Ltd.